Expert Interview
A Second View: Discussing the recent FDA accelerated approval for Fabhalta® (iptacopan) in patients with IgA nephropathy (IgAN)
Ticker(s): NVSInstitution: Albert Einstein College of Medicine | Montefiore
- Nephrologist & Professor of Medicine at Albert Einstein College of Medicine.
- Manages treatment for 30 patients with moderate-to-severe pruritus associated with chronic kidney disease, has not prescribed KORSUVA but is very familiar with the oral KORSUVA trial data.
- Has published over 100 manuscript and book chapters and practice focuses on nephrology and dialysis.
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
